Boston Scientific Q4 2024 Earnings Report
Key Takeaways
Boston Scientific reported a strong fourth quarter and full year 2024, with net sales reaching $4.561 billion in Q4, a 22.4% increase. The company's adjusted EPS for Q4 was $0.70, compared to $0.55 a year ago. Full year net sales were $16.747 billion, with adjusted EPS of $2.51.
Net sales increased by 22.4% in Q4 2024, reaching $4.561 billion.
Adjusted EPS for Q4 2024 was $0.70, up from $0.55 in the prior year period.
MedSurg segment net sales grew by 12.4%, while Cardiovascular segment net sales increased by 28.8%.
The company completed acquisitions of Axonics, Inc. and Cortex, Inc.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Forward Guidance
The company estimates net sales growth for the full year 2025 to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and approximately 10 to 12 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS of $2.80 to $2.87.
Positive Outlook
- Full year 2025 net sales growth is expected to be in the range of 12.5% to 14.5% on a reported basis.
- Full year 2025 organic net sales growth is projected to be between 10% and 12%.
- Full year 2025 EPS is estimated to be between $1.86 and $1.93 on a GAAP basis.
- Adjusted EPS for the full year 2025 is expected to be in the range of $2.80 to $2.87.
- First quarter 2025 net sales growth is anticipated to be in the range of 17% to 19% on a reported basis.
Challenges Ahead
- Full year organic net sales guidance excludes the impact of foreign currency fluctuations.
- Full year organic net sales guidance excludes net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
- First quarter organic net sales guidance excludes the impact of foreign currency fluctuations.
- First quarter organic net sales guidance excludes net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
- Estimates exclude certain charges (credits).
Revenue & Expenses
Visualization of income flow from segment revenue to net income